Study Of Ispinesib In Subjects With Breast Cancer

• Status: Completed
• Trial end date: 2006-08-25
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. In particular, this study will try is to find the answers to the following research questions:

1. Does breast cancer respond to Ispinesib?

2. What are the side effects of Ispinesib?

3. How much Ispinesib is in the blood at specific times after it is taken?

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Stage IIIB or Stage IV breast cancer

• Previously received anthracycline and taxane therapy

Exclusion criteria:

• Actively receiving anti-cancer therapy agent(s).